ABBV-467 is a selective MCL-1 inhibitor (Ki: <0.01 nM). ABBV-467 induces apoptosis. ABBV-467 induces cancer cell death and inhibits tumor growth in models of hematological malignancies, such as multiple myeloma.
ABBV-467 (1 nM - 10 μM, 24 h) inhibits BAK protein expression in BAK-deficient SKBR3 cells[1].ABBV-467 (0.01–10 nM, 24 hours) induces apoptosis in AMO-1 cell line[1].
ABBV-467 (12.5 mg/kg, i.v., once per week for 3 weeks) exhibits significant antitumor activity in t(4;14)-translocated multiple myeloma mouse models[1].
References:
[1]. Yuda J, et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med (Lond). 2023 Oct 25;3(1):154.